| Chair |
Lorenz Mayr, Novartis, Basel, CH
Sabine Adam, Congrex Switzerland Ltd., Basel, CH
Thilo Enderle, F. Hoffmann-La Roche, Basel, CH
Hubert Haag, Sanofi-aventis, Frankfurt, DE
Alexander Hillisch, Bayer-Schering, Wuppertal, DE
William Janzen, University of North Carolina, Chapel Hill, US
Vanessa King, Bioscale Inc., Cambridge, US
Al Kolb, KeyTech, Madison, US
Johannes Mosbacher, Actelion, Basel, CH
Anna Seelig, Biozentrum der Universität Basel, Basel, CH
Jost Harr, TZW AG, Witterswil, CH (BioValley Life Sciences Week)
|
| Chairs |
William Janzen, University of North Carolina, Chapel Hill, US
Johannes Mosbacher, Actelion, Basel, CH
Kurt Amreim, Roche, Basel, CH
Dominique Besson, World Health Organization, Geneva, CH
Mark Bickle, Max-Planck-Institute, Dresden, DE
Chas Bountra, Oxford University, Oxford, UK
Sabrina Corazza, Axxam, Milano, IT
Gregor Dernik, Roche, Basel, CH
Emilio Diez, GlaxoSmithKline S.A., Madrid, ES
Michael Entzeroth, Experimental Therapeutics Centre, Singapore
Stefan Ewert, Novartis, Basel, CH
Frank Fan, Promega Corporation, Madison, USA
Daniela Gabriel, Novartis, Basel, CH
Hubert Haag, Sanofi-Aventis, Frankfurt, DE
John Harris, BioFocusDPI, Cambridge, UK
Alexander Hillisch, Bayer-Schering, Wuppertal, DE
William Janzen, University of North Carolina, Chapell Hill, USA
Christopher Lipinski, Melior Discovery, Waterford, USA
Peter McLean, Nestlé, Lausanne, CH
Renate Schitzer, Boehringer-Ingelheim, Vienna, AT
Peter Schleiffer, ToolPoint, Zurich, CH
Michael Sundström, NNF Center, Copenhagen, DK
Nicolas Winssinger, Strasbourg University, Strasbourg, FR
|
